Search results
Results from the WOW.Com Content Network
An allergic transfusion reaction is when a blood transfusion results in allergic reaction. It is among the most common transfusion reactions to occur. Reported rates depend on the degree of active surveillance versus passing reporting to the blood bank. [1] [2] Overall, they are estimated to complicate up to 3% of all transfusions. [3]
Severe reactions may result in cutaneous necrosis at the injection site, typically presenting in one of two forms: (1) those associated with intravenous infusion or (2) those related to intramuscular injection. [7]: 123–4 Intramuscular injections may produce a syndrome called livedo dermatitis. [7]: 124
The combination of foscarbidopa and foslevodopa is indicated for the treatment of motor ... The most common adverse reactions include infusion/catheter site reactions ...
Anaphylactoid reaction, non-immune anaphylaxis, or pseudoanaphylaxis, is a type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation. [ 10 ] [ 42 ] Non-immune anaphylaxis is the current term, as of 2018, used by the World Allergy Organization [ 42 ] with some recommending that the old ...
Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies (such as insect bites) and asthma. [1] [2] Immunotherapy involves exposing people to larger and larger amounts of allergens in an attempt to change the immune system's response.
The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard ...
In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs. [3] It refers to cytokine storm syndromes (CSS) [ 4 ] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines ...
Makers of the new Alzheimer's drug, Leqembi, say their twice-monthly infusion could be available in injection form at pharmacies by early 2025 — if all goes well in ongoing trials and the ...